Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Medivir reports share and vote count increase after issues

EditorNatashya Angelica
Published 01/31/2024, 03:09 AM
Updated 01/31/2024, 03:09 AM
© Reuters.

STOCKHOLM - Medivir AB (NASDAQ Stockholm: MVIR), a biopharmaceutical company specializing in cancer drug development, announced today an increase in its number of shares and votes following recent share issues. The company completed a rights issue on November 7, 2023, and a directed share issue to Hallberg Management AB on January 22, 2024. These transactions resulted in a total increase of 56,211,817 ordinary shares.

As of the last trading day of January, Medivir has a total of 112,917,968 shares, comprising 112,053,218 ordinary shares and 864,750 class C-shares. The total number of votes amounts to 112,139,693, with each ordinary share entitled to one vote and each class C-share entitled to one-tenth of a vote.

Medivir's operations are centered on the development of innovative drugs for cancer treatment, specifically in areas with high unmet medical needs. The company's current focus is on fostroxacitabine bralpamide (fostrox), a pro-drug aimed at treating liver cancer with minimal side effects. Collaborations and partnerships are a significant aspect of Medivir's business strategy, with drug development being pursued independently or in conjunction with partners.

The company's share is listed on the Nasdaq Stockholm Small Cap list. This information, required to be disclosed under the Swedish Financial Instruments Trading Act, was released for publication at the time stated by the company's news distributor.

The announcement of the share and vote increase is based on a press release statement from Medivir.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.